Here, we developed a novel BCMA/CD47-directed UCAR-T therapy in which deletion of B2M and TRAC prevents life-threatening GvHD while effectively killing primary human MM cells and MM cell lines in vitro and in vivo. Here, CD47 is linked to Miyoshi myopathy.